{"id":18026,"date":"2023-04-28T12:55:33","date_gmt":"2023-04-28T12:55:33","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/?page_id=18026"},"modified":"2024-03-15T11:12:42","modified_gmt":"2024-03-15T09:12:42","slug":"adverse-event-reporting","status":"publish","type":"page","link":"https:\/\/www.ipsen.com\/contact-us\/adverse-event-reporting\/","title":{"rendered":"Adverse Event Reporting"},"content":{"rendered":"\n
<\/p>\n \n
Global<\/p>\n \n\n
\n ipsen_lsmv_intake_prod@arisglobal.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Algeria<\/p>\n \n\n \n pharmacovigilance.algeria@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Australia<\/p>\n \n\n \n pharmacovigilance.australia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Austria<\/p>\n \n\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Belgium<\/p>\n \n\n \n pharmacovigilance.belgium@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Brazil<\/p>\n \n\n \n pharmacovigilance.brasil@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Canada<\/p>\n \n\n \n pharmacovigilance.canada@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n China<\/p>\n \n\n \n pharmacovigilance.china@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Hong Kong – PRC<\/p>\n \n\n \n pharmacovigilance.hongkong@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Colombia<\/p>\n \n\n \n pharmacovigilance.colombia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Czech Republic<\/p>\n \n\n \n pharmacovigilance.czech@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Denmark<\/p>\n \n\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Estonia<\/p>\n \n\n \n pharmacovigilance.baltic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Finland<\/p>\n \n\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n France<\/p>\n \n\n \n pharmacovigilance.france@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Germany<\/p>\n \n\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Greece<\/p>\n \n\n \n pharmacovigilance.greece@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Hungary<\/p>\n \n\n \n pharmacovigilance.hungary@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Ireland<\/p>\n \n\n \n pharmacovigilance.uk-ie@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Italy<\/p>\n \n\n \n pharmacovigilance.italy@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Japan<\/p>\n \n\n \n pv.japan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Kazakhstan<\/p>\n \n\n \n pharmacovigilance.kazakhstan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Latvia<\/p>\n \n\n \n pharmacovigilance.baltic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Lithuania<\/p>\n \n\n \n pharmacovigilance.baltic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Luxembourg<\/p>\n \n\n \n pharmacovigilance.belgium@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Mexico<\/p>\n \n\n \n pharmacovigilance.mexico@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Netherlands<\/p>\n \n\n \n pharmacovigilance.netherlands@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Norway<\/p>\n \n\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Poland<\/p>\n \n\n \n pharmacovigilance.poland@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Portugal<\/p>\n \n\n \n pharmacovigilance.portugal@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Romania<\/p>\n \n\n \n pharmacovigilance.romania@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Russian Federation<\/p>\n \n\n \n pharmacovigilance.russia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Saudi Arabia<\/p>\n \n\n \n pharmacovigilance.ksa@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Singapore<\/p>\n \n\n \n pharmacovigilance.sg@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Slovakia<\/p>\n \n\n \n pharmacovigilance.slovakia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n South Korea<\/p>\n \n\n \n pharmacovigilance.korea@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Spain<\/p>\n \n\n \n pharmacovigilance.spain@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Sweden<\/p>\n \n\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Switzerland<\/p>\n \n\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Taiwan<\/p>\n \n\n \n pharmacovigilance.taiwan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Tunisia<\/p>\n \n\n \n pharmacovigilance.tunisie@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Ukraine<\/p>\n \n\n \n pharmacovigilance.ukraine@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n